Published in J Clin Oncol on October 31, 2011
Genomic Analysis to Identify a Predictive Biomarker for Immunotherapy (LC_Biomarker) | NCT03578185
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. J Clin Oncol (2014) 2.78
Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J Clin Oncol (2013) 2.70
Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res (2014) 2.27
Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res (2012) 2.09
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer (2014) 2.08
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Meta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes. Oncotarget (2012) 1.31
The determinants of tumour immunogenicity. Nat Rev Cancer (2012) 1.28
PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol (2012) 1.24
The Chemokine CXCL8 in Carcinogenesis and Drug Response. ISRN Oncol (2013) 1.22
Etiologic field effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol (2014) 1.16
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 1.12
Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor α and β chains using next-generation sequencing (NGS). Oncoimmunology (2015) 1.11
Macrophages are critical effectors of antibody therapies for cancer. MAbs (2015) 1.09
VISTA Regulates the Development of Protective Antitumor Immunity. Cancer Res (2014) 1.09
Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res (2014) 1.08
Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood (2013) 1.07
Toward integrative cancer immunotherapy: targeting the tumor microenvironment. J Transl Med (2012) 1.04
Lung cancer: Biology and treatment options. Biochim Biophys Acta (2015) 1.02
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99
Immunotherapy in ovarian cancer. Hum Vaccin Immunother (2012) 0.99
Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. Cancer Sci (2015) 0.97
Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2013) 0.95
Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol Rev (2014) 0.93
Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93
Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol (2015) 0.93
Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma. Neoplasia (2012) 0.93
Expression pattern of tumour-associated antigens in hepatocellular carcinoma: association with immune infiltration and disease progression. Br J Cancer (2013) 0.93
Immunotherapy at large: the road to personalized cancer vaccines. Nat Med (2013) 0.93
Immunocompetent murine models for the study of glioblastoma immunotherapy. J Transl Med (2014) 0.92
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. Br J Pharmacol (2016) 0.91
The future of glioblastoma therapy: synergism of standard of care and immunotherapy. Cancers (Basel) (2014) 0.91
Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3. Proc Natl Acad Sci U S A (2012) 0.91
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother (2014) 0.90
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccin Immunother (2016) 0.89
Haematological malignancies: at the forefront of immunotherapeutic innovation. Nat Rev Cancer (2015) 0.88
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines. Int J Cancer (2012) 0.88
Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res (2014) 0.87
The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers. Int J Oncol (2014) 0.87
Dendritic cells, inflammation, and breast cancer. Cancer J (2013) 0.86
Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology (2015) 0.86
Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS One (2013) 0.85
The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res (2015) 0.85
Antitumor and Adjuvant Activity of λ-carrageenan by Stimulating Immune Response in Cancer Immunotherapy. Sci Rep (2015) 0.85
Nivolumab in the treatment of malignant melanoma: review of the literature. Onco Targets Ther (2015) 0.84
T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. Front Immunol (2016) 0.84
Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res (2013) 0.84
A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. J Hematol Oncol (2014) 0.83
Hepatotoxicity of molecular targeted therapy. Contemp Oncol (Pozn) (2014) 0.83
Synergistic antitumor activity of reversine combined with aspirin in cervical carcinoma in vitro and in vivo. Cytotechnology (2013) 0.82
Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer. AAPS J (2014) 0.82
T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases. Front Physiol (2012) 0.81
A therapeutic microparticle-based tumor lysate vaccine reduces spontaneous metastases in murine breast cancer. AAPS J (2014) 0.81
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. Oncologist (2015) 0.81
Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma. Core Evid (2012) 0.81
Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med (2015) 0.80
PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. Mol Clin Oncol (2014) 0.80
Antitumor activity of human hydatid cyst fluid in a murine model of colon cancer. ScientificWorldJournal (2013) 0.80
Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells. Immunology (2014) 0.79
Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153. PLoS One (2015) 0.78
Promising targets and current clinical trials in metastatic squamous cell lung cancer. Front Oncol (2014) 0.78
HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology (2015) 0.78
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. Invest New Drugs (2016) 0.78
Awareness and understanding of cancer immunotherapy in Europe. Hum Vaccin Immunother (2014) 0.77
Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res (2015) 0.77
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration. Int J Clin Oncol (2015) 0.77
PD-L1 gene expression in Japanese lung cancer patients. Biomed Rep (2012) 0.76
The regulatory effect of UL-16 binding protein-3 expression on the cytotoxicity of NK cells in cancer patients. Sci Rep (2014) 0.76
Enhancement of anti-tumor CD8 immunity by IgG1-mediated targeting of Fc receptors. MAbs (2014) 0.76
Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells. Front Oncol (2014) 0.75
Evaluation of prognostic significance of granulocyte-related factors in cancer patients undergoing personalized peptide vaccination. Hum Vaccin Immunother (2015) 0.75
Global progress against cancer-challenges and opportunities. Cancer Biol Med (2013) 0.75
Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells. Oncotarget (2016) 0.75
Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother (2014) 0.75
Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional. Cytokine (2015) 0.75
Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option? J Kidney Cancer VHL (2014) 0.75
Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma. Therap Adv Gastroenterol (2016) 0.75
Variable epitope library carrying heavily mutated survivin-derived CTL epitope variants as a new class of efficient vaccine immunogen tested in a mouse model of breast cancer. Hum Vaccin Immunother (2014) 0.75
Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer. Oncol Ther (2016) 0.75
More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. PLoS One (2016) 0.75
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor. J Cancer (2017) 0.75
Immunotherapy-associated autoimmune hemolytic anemia. J Immunother Cancer (2017) 0.75
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget (2016) 0.75
NKp46 recognizes the sigma1 protein of reovirus: Implications for reovirus-based cancer therapy. J Virol (2017) 0.75
Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies. Front Pharmacol (2017) 0.75
Targeted therapies for renal cell carcinoma. Nat Rev Nephrol (2017) 0.75
Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40(+) monocyte differentiation. J Hematol Oncol (2017) 0.75
Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med (2000) 13.24
Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med (2007) 12.73
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol (2008) 8.17
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
The B7-CD28 superfamily. Nat Rev Immunol (2002) 7.24
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A (2010) 6.20
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med (2010) 5.92
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 5.79
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Epitope landscape in breast and colorectal cancer. Cancer Res (2008) 5.29
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Human T cell responses against melanoma. Annu Rev Immunol (2006) 4.99
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol (2001) 4.84
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A (1989) 4.63
A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother (2002) 4.31
Does the immune system see tumors as foreign or self? Annu Rev Immunol (2001) 3.71
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res (2010) 3.02
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res (2009) 2.97
CARs on track in the clinic. Mol Ther (2011) 2.86
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A (1998) 2.78
Rituximab: mechanism of action. Semin Hematol (2010) 2.66
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res (2010) 2.64
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol Ther (2009) 2.52
Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res (2004) 2.41
Cancer vaccines. Nat Med (1998) 2.22
Immune regulation of cancer. J Clin Oncol (2010) 1.99
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol (2005) 1.91
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med (2011) 1.80
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood (2006) 1.79
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood (2007) 1.69
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med (1994) 1.60
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2. J Clin Oncol (1994) 1.60
Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J (2010) 1.52
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest (2007) 1.51
Clinical development of the anti-CTLA-4 antibody tremelimumab. Semin Oncol (2010) 1.47
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46
Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res (2008) 1.32
Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol (2008) 1.31
Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther (2004) 1.29
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs (2009) 1.26
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplant (2007) 1.24
The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev (2008) 1.22
Human tumor antigens recognized by T-cells. Immunol Res (1997) 1.18
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst (2011) 1.09
Allogeneic transplantation for lymphoma. J Clin Oncol (2011) 1.07
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk Lymphoma (2009) 1.05
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J (2010) 1.03
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood (2009) 1.03
Discontinued drugs in 2005: oncology drugs. Expert Opin Investig Drugs (2006) 0.86
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
A human colonic commensal promotes colon tumorigenesis via activation of T helper type 17 T cell responses. Nat Med (2009) 7.45
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol (2012) 7.26
Expression of programmed death 1 ligands by murine T cells and APC. J Immunol (2002) 5.78
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med (2009) 5.05
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol (2007) 4.29
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res (2011) 3.81
Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 3.71
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med (2006) 3.49
Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol (2003) 3.12
Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. Blood (2007) 3.00
Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 3.00
Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells. Blood (2007) 2.93
Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma. Cancer Res (2013) 2.81
In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol (2009) 2.76
Eos mediates Foxp3-dependent gene silencing in CD4+ regulatory T cells. Science (2009) 2.76
LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest (2007) 2.57
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol (2010) 2.06
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood (2010) 1.83
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood (2006) 1.79
Cancer and inflammation: promise for biologic therapy. J Immunother (2010) 1.72
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma (2011) 1.71
Cutting edge: Expression of functional CD137 receptor by dendritic cells. J Immunol (2002) 1.70
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood (2007) 1.69
Retracted Cross-linking the B7 family molecule B7-DC directly activates immune functions of dendritic cells. J Exp Med (2002) 1.68
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells. Mol Immunol (2010) 1.65
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods (2005) 1.62
Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. Immunity (2012) 1.61
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol (2009) 1.60
Constitutive and inducible expression of b7 family of ligands by human airway epithelial cells. Am J Respir Cell Mol Biol (2005) 1.56
Tc17 CD8 T cells: functional plasticity and subset diversity. J Immunol (2009) 1.54
Perspective: alpha-bugs, their microbial partners, and the link to colon cancer. J Infect Dis (2010) 1.53
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51
B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res (2005) 1.49
Differential binding properties of B7-H1 and B7-DC to programmed death-1. Biochem Biophys Res Commun (2003) 1.49
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget (2014) 1.47
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res (2013) 1.47
Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. Clin Cancer Res (2007) 1.47
Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood (2011) 1.47
IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res (2010) 1.45
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother (2006) 1.44
A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res (2008) 1.36
LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 1.33
B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. Biochem Biophys Res Commun (2007) 1.29
Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc Natl Acad Sci U S A (2007) 1.28
Cellular vaccine approaches. Cancer J (2010) 1.27
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res (2006) 1.25
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood (2006) 1.25
Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother (2007) 1.24
Retracted Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells. J Immunol (2003) 1.21
Feedback inhibition of calcineurin and Ras by a dual inhibitory protein Carabin. Nature (2007) 1.21
Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis. J Clin Invest (2006) 1.20
CD4+ T cells pass through an effector phase during the process of in vivo tolerance induction. J Immunol (2003) 1.19
Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol (2003) 1.18
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate (2008) 1.17
Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci U S A (2005) 1.14
CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther (2008) 1.14
Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol (2004) 1.13
Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood (2009) 1.13
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum Gene Ther (2003) 1.09
Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst (2011) 1.09
Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res (2007) 1.08
CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res (2003) 1.07
Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells. J Immunol (2009) 1.07
GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present. Leuk Lymphoma (2013) 1.05
AACR Cancer Progress Report 2014. Clin Cancer Res (2014) 1.05
Integrin alpha2 mediates selective metastasis to the liver. Cancer Res (2009) 1.03
A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles. J Pharm Sci (2007) 1.01
Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. J Immunol Methods (2002) 1.00
Immunotherapy of established tumors using bone marrow transplantation with antigen gene--modified hematopoietic stem cells. Nat Med (2003) 1.00
The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement. Immunogenetics (2006) 1.00
Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol (2008) 0.99
Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine. Cancer Res (2005) 0.98
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res (2004) 0.97
AACR Cancer Progress Report 2013. Clin Cancer Res (2013) 0.95
Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling. Cancer Res (2006) 0.94
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol (2011) 0.93
Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 0.93
Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. Mol Cancer Ther (2005) 0.92
CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol (2003) 0.91
CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs (2003) 0.91
Aging-associated B7-DC+ B cells enhance anti-tumor immunity via Th1 and Th17 induction. Aging Cell (2011) 0.90